COMMUNIQUÉS West-GlobeNewswire
-
Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program
16/11/2026 -
FOR INVESTORS AND FINANCIAL AND BUSINESS MEDIA ONLY Renaissance Pharma secures FDA Breakthrough Therapy Designation for daretabart in newly diagnosed high-risk neuroblastoma
16/11/2026 -
Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
16/11/2026 -
Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
16/11/2026 -
Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
16/11/2026 -
RAMSAY SANTE : nouvelle gouvernance
16/11/2026 -
RAMSAY SANTE : new governance
16/11/2026 -
Philips to nominate Dick Boer, Laurence Debroux and Todd Brinton to its Supervisory Board at the 2027 Annual General Meeting of Shareholders (AGM)
16/11/2026 -
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
16/11/2026 -
Mesoblast Showcased at ASX Premier Investor Day Event
16/11/2026 -
Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
16/11/2026 -
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026
15/11/2026 -
NeuroKaire To Showcase Breakthrough Blood Test That Ends the Antidepressant Guessing Game at HLTH 2026 Conference
15/11/2026 -
Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026
15/11/2026 -
Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results
15/11/2026 -
Keto-Mojo Unveils World’s First Photoacoustic Breathalyzer, Advancing Non-Invasive Ketone Monitoring
14/11/2026 -
Grassroot Soccer Honors U.S. Soccer at 2026 Gala, Raising over $2 million for Adolescent Health Programs
15/11/2026 -
Prolynx Presents Preclinical Data at ObesityWeek® 2026 Supporting the Potential for Quarterly Dosing of Ultra-Long-Acting Anti-Obesity Peptides
14/11/2026 -
Oban BioPharma Announces Presentation of Late-Breaking Abstract at Obesity Week® 2026
14/11/2026
Pages